A one-month real-world review of the Blackmagic PYXIS 12K. Image quality, RAW workflow, pros, cons, and who this full-frame camera is really for.
Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.
As of Thursday, December 18, Pyxis Oncology, Inc.’s PYXS share price has dipped by 53.39%, which has investors questioning if ...
ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kg Updated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC ...
Well, this is a nice surprise to wake up to if you’re a Blackmagic PYXIS (6K or 12K) or URSA Broadcast G2 owner. The latest ...
Having recently trimmed back its pipeline to a sole cancer candidate, Pyxis Oncology has now reduced its head count to match. The Boston biotech is shrinking its workforce by "approximately" 20%, it ...
Pyxis Oncology, Inc. (PYXS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...
Pyxis Oncology needs to pave a longer cash runway. To do so, the Pfizer-partnered antibody-drug conjugate (ADC) biotech is cutting 40% of staff, slimming its programs and looking to monetize royalty ...
Lara Sullivan, Pyxis Oncology CEO, joins Yahoo Finance to discuss the biotech company going public and its oncology treatments for patients with difficult-to-treat cancer. JARED BLIKRE: Well, an IPO ...
The monotherapy trial suggested a confirmed overall-response rate of 46% and a disease-control rate of 93%. In combination with Keytruda, the confirmed overall-response rate was 71% and the ...
The round is backed by Shift4Good, Motion Ventures, SG Growth Capital & Mol Plus Proceeds will be channelled towards scaling ...
Welcome to Indie App Spotlight. This is a weekly 9to5Mac series where we showcase the latest apps in the indie app world. If you’re a developer and would like your app featured, get in contact. Pyxis ...